Amphetamines (AMP) antibody and antigen (hapten, BSA/OVA conjugated)

Diagnostic anti-Amphetamines (AMP) antibodies (anti-Amphetamines, anti-AMP) and diagnostic hapten-carrier conjugates BSA-Amphetamines (AMP), OVA-Amphetamines (AMP), KLH-Amphetamines (AMP) antigens for Multiple disease AMP detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Target products collectionGo to Multiple disease diagnostics products collection>>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-223-Ag01BSA-Amphetamines (AMP)$756.00
GMP-SMT-223-Ag02OVA-Amphetamines (AMP)$756.00
GMP-SMT-223-Ab01Anti-human Amphetamines (AMP) mouse monoclonal antibody (mAb)$1953.00
GMP-SMT-223-Ab02Anti-human Amphetamines (AMP) human monoclonal antibody (mAb)$1953.00

Size: 1mg | 10mg | 100mg



Product Description

BSA-Amphetamines (AMP)

Cat No.GMP-SMT-223-Ag01
Product NameBSA-Amphetamines (AMP)
TargetAmphetamines (AMP)
Expression platformSynthetic
Bioactivity validationAmphetamines (AMP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in AMP level test of Multiple disease (ADHD, narcolepsy) and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Amphetamines (AMP) / OVA-Amphetamines (AMP) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

OVA-Amphetamines (AMP)

Cat No.GMP-SMT-223-Ag02
Product NameOVA-Amphetamines (AMP)
TargetAmphetamines (AMP)
Expression platformSynthetic
Bioactivity validationAmphetamines (AMP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in AMP level test of Multiple disease (ADHD, narcolepsy) and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Amphetamines (AMP) / OVA-Amphetamines (AMP) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Amphetamines (AMP) mouse monoclonal antibody (mAb)

Cat No.GMP-SMT-223-Ab01
Product NameAnti-human Amphetamines (AMP) mouse monoclonal antibody (mAb)
TargetAmphetamines (AMP)
Expression platformhybridoma
IsotypesMouse IgG
Bioactivity validationAmphetamines (AMP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Amphetamines (AMP) antibodies in AMP level test of Multiple disease (ADHD, narcolepsy) and related syndrome evaluation.
TagmFc
Products descriptionAnti-human Amphetamines (AMP) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Amphetamines (AMP) human monoclonal antibody (mAb)

Cat No.GMP-SMT-223-Ab02
Product NameAnti-human Amphetamines (AMP) human monoclonal antibody (mAb)
TargetAmphetamines (AMP)
Expression platformhybridoma
IsotypesHuman IgG1
Bioactivity validationAmphetamines (AMP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Amphetamines (AMP) antibodies in AMP level test of Multiple disease (ADHD, narcolepsy) and related syndrome evaluation.
TaghFc
Products descriptionAnti-human Amphetamines (AMP) mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO.
PurityPurity: ≥95% (SDS-PAGE)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationSupplied as a 0.2 μM filtered solution of PBS, PH7.4.
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Target/Biomarker information


    1. Detailed Overview of Amphetamines in In Vitro Diagnostic Applications

    Amphetamines are a class of psychoactive compounds that act as central nervous system (CNS) stimulants, promoting increased alertness, concentration, and energy, alongside a sense of euphoria. These substances are prescribed for a range of medical conditions, including Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, and certain cases of treatment-resistant obesity. The pharmacological action of amphetamines involves the increased release of neurotransmitters such as dopamine and norepinephrine in the brain, which contributes to their stimulant effects and potential for addiction.

    In the realm of in vitro diagnostics (IVD), the detection and quantification of amphetamines are paramount, particularly for therapeutic drug monitoring (TDM), substance abuse screening, anti-doping in sports, and forensic toxicology. The development of specific anti-amphetamine antibodies and competitive antigens, including technologies such as carrier-coupled antigens, hapten-carrier conjugates, and protein conjugates (BSA and OVA-conjugated), underpins the sensitivity and specificity of immunoassays used for these purposes. These diagnostic assays are designed to accurately identify and measure amphetamine levels in various biological samples, including blood, urine, and saliva, offering critical insights into drug metabolism, compliance, and potential abuse.

    2. Rationale for Amphetamine Quantification in Clinical and Forensic Settings

    The measurement of amphetamine levels serves several critical functions across clinical and forensic contexts:

    Therapeutic Drug Monitoring (TDM): For patients prescribed amphetamine-based medications, TDM is essential to ensure that drug concentrations stay within a therapeutic range. This balancing act helps achieve the intended clinical benefits while minimizing adverse effects and the risk of dependency. Personalized dosing adjustments, informed by precise drug level measurements, can significantly improve treatment outcomes for individuals with ADHD, narcolepsy, and obesity.

    Substance Abuse Monitoring: The high potential for abuse and dependence on amphetamines necessitates robust screening and monitoring protocols, especially in rehabilitation settings. Quantitative drug testing supports the management of addiction and the evaluation of treatment efficacy, providing a basis for tailored intervention strategies.

    Workplace Safety and Compliance: In occupations where alertness and safety are paramount, amphetamine testing is a critical component of workplace drug policies. Detecting amphetamine use helps maintain a safe work environment, ensuring employees are not under the influence of substances that could impair their judgment or performance.

    Anti-Doping in Sports: Given their performance-enhancing effects, amphetamines are banned in most competitive sports. Rigorous testing for these substances is crucial to uphold the integrity of sports, ensuring a level playing field and protecting athletes' health.

    Forensic and Legal Investigations: In legal contexts, precise amphetamine measurement can provide evidence of substance abuse or contribute to the assessment of an individual's state at the time of an incident, impacting legal judgments and proceedings.

    Advanced diagnostic methodologies, including enzyme-linked immunosorbent assay (ELISA), mass spectrometry, and chromatography techniques, are employed to achieve the high sensitivity and specificity required for amphetamine detection. The integration of innovative IVD tools and assays facilitates the accurate and reliable analysis of amphetamine levels, supporting a wide range of applications from clinical therapeutics to legal and regulatory compliance. This comprehensive approach underscores the importance of continued innovation and development in the field of in vitro diagnostics, ensuring that healthcare providers, regulatory bodies, and law enforcement agencies have access to the data needed to make informed decisions.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.